Gabriel Ott
Co-Founder and CEO, Dinari. On 1 show, 3 appearances. The Shows tab opens the full record on each.
founderexecutiveengineerinvestor@GabeOtte ↗LinkedIn ↗dinari.com ↗
Gabriel Otte is best known as the co-founder and former CEO of Freenome, a biotechnology company developing machine learning–driven blood tests for early cancer detection. He currently leads Dinari, a financial infrastructure company focused on tokenizing real-world assets and U.S. securities.
1shows
3appearances
24statements
8resolved
4supported
2contradicted
50%fully supported
Everything Gabriel Ott said on any show that made the record, most notable first. Each card names its show and opens the statement there.
Otte: Insurance payers and clinicians are blocking diagnostic innovation
“It's really the payers and some of the clinicians that are being the inhibitors to this progress.”
Ott: Dynamic DNA testing will enable detection of any disease with immune changes
“The underlying biology should theoretically enable us to detect any diseases where there is an immune change.”
Ott: Mammography Screenings Have a 50% False Positive Rate
“Breast cancer, and specifically mammography as a screening method, has a false positive rate of 50%.”
Otte: PSA tests and mammograms have false positive rates up to 75%
“In the field of cancer screening, cancer diagnostics, we're used to, like, really, really bad tests. So like PSA for prostate cancer detection, mammography for breast cancer detection, these things have false positive rates of anywhere from, ah, 50 to 75%.”
Ott: Single-gene targeted approaches fail for early cancer detection
“What sometimes happens when you are very focused though, is you missed a bigger picture. And what we're realizing is with respect to things like detecting cancer early, that focused approach is not working.”
Freenome detects dynamic cell-free DNA from circulating immune cells
“What we're detecting is DNA fragments that are actually coming from the immune cells that are turning over in your body.”
AI diagnostics can continuously improve accuracy post-launch by learning from results
“Because we can now make a diagnostic that's fundamentally AI-based, even after we launch the test into the market, we can actually work with our partners to get results of the test that we sell back so that we can teach the artificial intelligence that it made…”
Ott: Only 20% of new diagnostic tests receive full reimbursement
“If you're looking at the average statistics, generally when you're launching a diagnostic test, only about 20% of the tests that you sell actually get fully reimbursed.”
Otte: Expecting one genome snapshot to answer disease questions is ludicrous
“The fact that we thought taking one person's genome at one snapshot was going to answer every, you know, question about diseases and things like that was just ludicrous in retrospect.”
Otte: 80% of US cancer spending goes toward end-of-life care
“80% of all the money that we spend on treating and dealing with cancer in the healthcare system in the United States, something about between 75 and a hundred billion dollars a year, is to help people die of cancer. That's what we spend 80% of the money on rig…”
Otte: The average human produces 12 cancer cells every minute
“On average, an average human being makes, you know, 12 cancer cells every minute.”
Ott: Early detection increases cancer survival rates to 97% versus late-stage treatments
“The best drugs that we have today to treat cancer called immunotherapies only give you about 30 to 40% chance of five-year survival in treatment. These are the best drugs that we have. Chemotherapy and radiation give you less than 20%. Chance of survival. On t…”
Ott: No single silver-bullet drug will ever cure all cancers
“With that in mind, I think a lot of us like to think that it's going to be the next greatest drug that's going to cure cancer. It's going to be that, you know, silver bullet. There isn't really going to be a silver bullet in my mind to treating a hundred diffe…”
Ott: Knowing a 30% lifetime cancer risk is not empowering without action
“It's not really empowering to the consumer to know that they're going to have a 30% chance of getting cancer sometime in their life.”
Ott: Illumina effectively holds a justified monopoly in DNA sequencing hardware
“Illumina effectively is a monopoly in the space of DNA sequencing, and in a lot of ways, rightly so.”
Diagnostic tests will increasingly leverage non-traditional payment models like life insurance
“I think we're going to see leveraging of these new models much more, but it's still in the early days.”
Ott: Machine learning maturity is accelerating genomics research
“What's different now as opposed to what was happening in 2000 is finally the technology, the machine learning techniques, as well as the hardware supporting that has matured to a point where we don't have to try to manually figure this complicated system out b…”
Ott: DNA sequencing cost reductions have outpaced Moore's Law by magnitudes
“And it's beat Moore's law by several magnitudes.”
Ott: Well-studied cancer driver genes represent less than 1% of the genome
“The genes that I mentioned, we're really talking about less than one percent of the entire genome. And so there's this 99.99% of the genome that hasn't really been understood in terms of how they affect people's bodies and how these diseases come out from othe…”
Ott: Science has not solved which biological signatures best detect disease early
“Yes, there are signatures early on that indicate whether there is a tumor or not. But what hasn't been solved yet is exactly what are those signatures that allow us to detect those diseases? And what are the best signatures for us to detect them most accuratel…”
Ott: 35 Million Americans Missed Colorectal Cancer Screenings Last Year
“Last year, thirty-five million people should have gotten screened for colorectal cancer in the United States alone and didn't.”
Otte: 23andMe analyzes less than one percent of the human genome
“You can do things like 23 and me, which looks at less than one percent of the entire genome, looking at specific mutations that you were born with, and what that can tell you about who you're going to be.”
Otte: Genomic research is severely bottlenecked by lack of phenotypic data
“What's been severely lacking is a deeper understanding of the phenotypic information that we can associate back to genomic information, something that almost everyone that's doing research in genomics would agree it's really hard information to get, and It's r…”
One line per show, most statements first. The link opens Gabriel's full record on that show: the calibration, argument clarity, speaking style and every statement made there.
| Show | Role there | Eps | Statements | Record | |
|---|---|---|---|---|---|
 a16zLEDGER | Co-Founder and CEO, Dinari | 3 | 24 | 50% 4/8 | full record on the a16z Podcast → |